Global Liver Diseases Therapeutics Market: Industry Analysis, Size, Share, Trends and Forecast 2012 – 2018
Transparency Market Research has published a new report titled "Global Liver Diseases Therapeutics Market: Industry Analysis, Size, Share, Trends and Forecast 2012 – 2018" to its report store. Browse the full report: http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html.
Albany, New York (PRWEB) June 25, 2014
The report on “Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) – Global Industry Analysis, Size, Share, Trends And Forecast, 2012 – 2018” studies the performance of the different drugs class segments that are employed in liver disease therapeutics. These performance analyses have been performed based on revenue. The report provides the market size of the liver diseases therapeutics market before carrying out a comparative analysis of the global liver disease therapeutics market based on drug class. The first two chapters offer an orientation of the general trends in the liver diseases therapeutics market.
Browse the full Liver Diseases Therapeutics Market Report: http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html.
It further touches upon the various market drivers that have created numerous opportunities within this market—such as an aging population, a rise in the global prevalence of liver disease, the presence of high unmet needs in liver cancer therapeutics, and the increasing volume of vaccination in developing economies. Furthermore, this data-driven report also offers insights into factors that could prove to be impediments to the ideal growth of this market. These include: side effects and risks associated with some of these drugs, government regulations as well as FDA approvals, and the availability of alternative treatments to patients.
The report classifies the global liver diseases therapeutics market based on the key prevailing drug class segments. These seven segments are immunosuppressants, anti-viral drugs, immunoglobulins, chemotherapy, targeted therapy, vaccines, and corticosteroids. Going ahead, the report also provides detailed estimates and forecasts of the market size from 2012 – 2018, coupled with the compounded annual growth rate (CAGR) of each of these segments.
Request for customization of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=799.
This report has been designed to offer users an unmatched competitive edge, and hence features an in-depth competitive landscape of the liver diseases therapeutics market, with complete company profiles of market players that matter. These include names such as: Astellas Pharma Inc, Novartis, Abbott Laboratories, Gilead Science Inc., Pfizer, Merck & Co., Roche, as well as Bristol-Myers Squibb, among others. The report presents a complete analysis of the company overview, business strategies, product portfolio, recent developments, and a financial overview of these companies.
The report answers questions pertaining to the performance of liver diseases therapeutics in the worldwide market, as well as the role played by emerging markets in their performance. The report is based on in-depth and accurate primary and secondary research methodologies that have been perfected by the research team at Transparency Market Research. Our findings are further validated via analysis and consultations with C-level executives working with major companies in the liver diseases therapeutics market.
The report classifies liver diseases and therapy options as follows:
- Alcohol induced liver disease
- Autoimmune liver disorder
- Hepatocellular carcinoma
- Non-alcoholic fatty liver disease
- Viral/hepatitis liver disorder
The report also studies the liver diseases therapeutics market based on drug class, as follows:
- Chemotherapy drugs
- Targeted therapy drugs
- Anti-viral drugs
90 Sate Street, Suite 700
Albany, NY 12207
USA/Canada Toll Free: 866-552-3453
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/06/prweb11973466.htm